The National Institutes of Health, through its NIH Guide, has recently published the following funding-related notices and funding opportunities:

Policy Notices

• Salary Limitation on AHRQ FY2023 Grants, Cooperative Agreements, and Contracts
  (NOT-HS-23-005)
  Agency for Healthcare Research and Quality

General Notices

• Notice to Extend the Response Date for NOT-CA-23-011, "Request for Information (RFI) on Challenges and Opportunities Associated with Multidimensional Tumor Atlases"
  (NOT-CA-23-033)
  National Cancer Institute

• Notice of NIBIB Specific Interests and Guidance in RFA-NS-23-007 "HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
  (NOT-EB-22-013)
  National Institute of Biomedical Imaging and Bioengineering

• Notice of NIBIBs Withdrawal form Participation in RFA-HG-21-041 New Investigators to Promote Workforce Diversity in Genomics, Bioinformatics, or Bioengineering and Biomedical Imaging Research (R01 Clinical Trial Optional).
  (NOT-EB-22-014)
  National Institute of Biomedical Imaging and Bioengineering

• Notice of NIBIB's Participation in PAR-22-181, " NCCIH, NEI, NIAAA, NIDA, NIMH, NINR, and NINDS Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)
  (NOT-EB-22-015)
  National Institute of Biomedical Imaging and Bioengineering

• Notice of Correction to Application Budget for PAR-23-050, "Clinical Studies of Mental Illness (Collaborative R01 Clinical Trial Optional)"
  (NOT-MH-23-170)
  National Institute of Mental Health

• Request for Information (RFI): Inviting Input Regarding NIDCDs Support of Non-Invasive Imaging in Humans
  (NOT-DC-23-004)
  National Institute on Deafness and Other Communication Disorders

Notice of Changes to Funding Opportunities

• Notice to Extend the Letter of Intent and Application Due Date for RFA-FD-23-014- " In Vivo Regional Deposition Measurements for Supporting Model Validation (U01) Clinical Trial Required"
  (NOT-FD-23-002)
  Food and Drug Administration

• Notice to Extend the Application Due Date for RFA-FD-23-009- Innovation Award: COVID-19 and Health Equity (U01) Clinical Trials Not Allowed
  (NOT-FD-23-003)
  Food and Drug Administration

• Notice to update Award Budget for PAR-23-072 "FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)"
  (NOT-FD-23-004)
  Food and Drug Administration

• Notice of Termination for PAR-22-122: Limited Competition: Clinical and Translational Science Awards (CTSA) Consortium-Wide Centers: Resources for Rapid Demonstration and Dissemination (U24 Clinical Trials Optional)
  (NOT-TR-23-005)
  National Center for Advancing Translational Sciences

Notices of Special Interest

• Notice of Special Interest (NOSI): Fundamental Science Research on the Neural Circuits Underlying Sensory Processing
  (NOT-DC-23-001)
  National Institute on Deafness and Other Communication Disorders

• Notice of Special Interest (NOSI): Support for existing data repositories to align with FAIR and TRUST principles and evaluate usage, utility, and impact
  (NOT-OD-23-044)
  Office of the Director, NIH
  National Center for Complementary and Integrative Health
  National Institute on Aging
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  National Library of Medicine

Funding Opportunities

• HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)
  (PAR-23-069)
  National Institute of Neurological Disorders and Stroke
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
   
• Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
  (PAR-23-088)
  National Cancer Institute
   
• Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)
  (PAR-23-091)
  National Institute of Mental Health
   
• Effectiveness of Implementing Sustainable Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Mental Health Equity for Traditionally Underserved Populations (R01 Clinical Trial Optional)
  (PAR-23-092)
  National Institute of Mental Health
   
• Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)
  (PAR-23-093)
  National Institute of Mental Health
   
• Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R01 Clinical Trial Required)
  (PAR-23-094)
  National Institute of Mental Health
   
• Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed)
  (PAR-23-095)
  National Institute of Mental Health
   
• Laboratories to Optimize Digital Health (R01 Clinical Trial Required)
  (PAR-23-096)
  National Institute of Mental Health
   
• Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
  (PAR-23-097)
  National Institute of Mental Health
   
• Pilot and Feasibility Trials on the Integration of Social and Medical Care for Type 1 Diabetes Mellitus (R01 Clinical Trial Required)
  (RFA-DK-22-028)
  National Institute of Diabetes and Digestive and Kidney Diseases
   
• BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development (UG3/UH3 Clinical Trial Not Allowed)
  (RFA-EB-22-003)
  National Institute of Biomedical Imaging and Bioengineering
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
   
• Development and Validation of a Multi-functional, Multi-purpose Quantitative Tool for Dermal Physiologically-Based Pharmacokinetic (PBPK) Modeling (U01) Clinical Trial Optional
  (RFA-FD-23-015)
  Food and Drug Administration
   
• Research Centers in Minority Institutions (RCMI) (U54 Clinical Trial Optional)
  (RFA-MD-23-001)
  National Institute on Minority Health and Health Disparities
   
• Tools and resources to understand the vascular pathophysiology of in vivo neuroimaging findings in TBI-related dementia and/or VCID (U24 - Clinical Trials Not Allowed)
  (RFA-NS-23-002)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging

Members of the University of Iowa community may direct questions to the UI Division of Sponsored Programs at dsp@uiowa.edu(link sends e-mail)  or 313-335-2123, or email Ann Ricketts at ann-ricketts@uiowa.edu(link sends e-mail) or Lynn Hudachek at lynn-hudachek@uiowa.edu(link sends e-mail).